Zymeworks ( (ZYME) ) has shared an update.
Zymeworks Inc. announced the achievement of a $14 million milestone payment from GSK as part of their collaboration on bispecific antibodies using Zymeworks’ Azymetric™ platform. This milestone underscores the successful partnership and highlights the potential for significant future financial benefits, including up to $1.1 billion in milestone payments and royalties, enhancing Zymeworks’ position in the biotechnology industry and offering promising implications for stakeholders.
More about Zymeworks
Zymeworks Inc. is a global clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics aimed at improving treatment standards for challenging diseases such as cancer, inflammation, and autoimmune disorders. The company leverages its proprietary Azymetric™ platform to engineer differentiated antibody-based therapeutic candidates and has established strategic partnerships to advance its pipeline.
YTD Price Performance: -5.62%
Average Trading Volume: 435,732
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $968.8M
Learn more about ZYME stock on TipRanks’ Stock Analysis page.